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INTRODUCTION
Lung transplantation has remained the only treatment option 
for chronic progressive lung disease since the first successful 
unilateral lung transplantation procedure in pulmonary fibro-
sis patients in 1983.1 However, median survival thereafter is rel-
atively low (5.9 years), compared with other solid organ trans-
plantation approaches. Notably, however, median survival 
increases to 8.1 years for patients who survive for the first year 
or more.2,3 Previous studies have revealed several factors relat-
ed to mortality, which could be used to predict prognosis.4-9 
However, quality of life and performance differ according to the 
degree of recovery of pulmonary function, even if patients sur-
vive after lung transplantation.
Lung function recovery is an important predictor of prog-
nosis in lung transplant recipients and is used as a diagnostic 
parameter for bronchiolitis obliterans syndrome (BOS).10 BOS 
is defined as a sustained decline in forced expiratory volume in 
1 second (FEV1).11 While inflammation, destruction of small 
airway, and fibrosis are putative mechanisms of BOS, this con-
dition is not easy to diagnose through biopsy. Therefore, lung 
function deterioration on pulmonary function test (PFT) has 
been suggested as a diagnostic criterion for BOS.11 Pulmonary 
function is known to be influenced by acute rejection, infection, 
recurrence of primary disease, and complication at the anasto-
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mosis site; therefore, early prediction of pulmonary function 
deterioration is an important factor for the survival of recipi-
ents.12-14 While increasing the 1-year survival rate to improve 
long-term survival rate is important, although lung function re-
covery also serves as an important prognostic factor for surviv-
ing patients.4 Notwithstanding, there has been no definitive 
study of factors affecting lung function recovery at the first year 
of lung transplantation. Thus, the purpose of this study was to 
identify factors affecting the recovery of pulmonary function in 
patients who survive for >1 year after lung transplantation.
MATERIALS AND METHODS
Study design and patient population 
We retrospectively reviewed the electronic medical records of 
lung transplantation patients in a single tertiary medical insti-
tution in South Korea for the period between October 2012 and 
June 2016. As described in Fig. 1, 109 patients underwent lung 
transplantation during the study period; 58 patients were in-
cluded in the study. Patients who died within one year after 
lung transplantation (n=47, 43.1%) or who did not complete 
PFTs (n=4, 3.7%) were excluded. A follow-up PFT was sched-
uled every 3 months after transplantation. The patients were 
divided into two groups according to whether they recovered 
to a normal range of FEV1 (FEV1 ≥80% of predicted value vs. 
<80%). The study protocol was approved by the Institutional 
Review Board (IRB) of Severance Hospital (IRB No. 4-2013-
0770).
Variables and definitions
We analyzed various clinical characteristics, including recipi-
ent, perioperative, postoperative, and donor factors. The re-
cipient factors included age, gender, body mass index (BMI), 
smoking history, transplant type, primary or underlying dis-
ease, and preoperative prognostic nutritional index (PNI). PNI 
was calculated using the following equation: [10×albumin (g/
dL) + 0.005×total lymphocyte count (per mm3)].15 Perioperative 
and postoperative factors, such as mechanical ventilator (MV) 
use or extracorporeal membrane oxygenation (ECMO) use 
before and after transplantation, intensive care unit (ICU) du-
ration, and hospitalization duration, were analyzed. Primary 
graft dysfunction (PGD) and acute rejection requiring steroid 
pulse therapy were also reviewed. PGD was scored based on 
the International Society of Heart and Lung Transplantation 
(ISHLT) criteria; grade 2–3 was classified as high-grade PGD.16 
Factors related to the operation included operation time, isch-
emic time, and size mismatch between donor and recipient. 
Donor information, such as age, gender, BMI, smoking history, 
total lung capacity (TLC), size match, arterial partial pressure of 
oxygen (PaO2), fraction of inspired oxygen (FiO2), and ventila-
tion time, was collected through the Korean Network for Organ 
Sharing. 
Statistical analysis
All statistical analyses were performed using SPSS Statistics 
version 23 (IBM Corp., Armonk, NY, USA). Unadjusted vari-
ables of study groups were analyzed by chi-squared test or 
Mann-Whitney test, then described as numbers (percentages) 
1 year PFT
Exclusion
Total lung transplantation patients
n=109 (2012. 10–2016. 06)
Group 1
FEV1≥80% (n=28)
Group 2
FEV1<80% (n=30)
n=58
Exclusion n=51
Expire within 1 year
1 year PFT were not performed
Fig. 1. Flow diagram of the study population. A total of 58 patients were enrolled in this study and divided into two groups. PFT, pulmonary function test; 
FEV1, forced expiratory volume in 1 second.
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or medians [ranges or interquartile ranges (IQRs)]. Relation-
ships between variables and lung function recovery were as-
sessed by logistic regression models for multivariate analysis. 
p values ≤0.05 were regarded as significant.
RESULTS
Characteristics of the patients
A total of 109 patients underwent lung transplantation during 
the study period; 58 patients who survived more than one year 
and who underwent PFTs at the first year after transplantation 
were enrolled. The patients were divided into two groups ac-
cording to their FEV1 values at 1 year after lung transplanta-
tion: 28 patients (48%) were classified as FEV1 ≥80% of the 
predicted value group (FEV1 ≥80% group); the remaining pa-
tients (52%), whose FEV1 was less than 80%, were classified into 
FEV1 <80% of the predicted value group (FEV1 <80% group). 
Baseline characteristics and variables of recipients are present-
ed in Table 1. Median age was significantly younger in the FEV1 
<80% group (55 years vs. 45 years, p=0.004). Gender, BMI, 
smoking history, and PNI were not significantly different be-
tween the two groups. Most operations were bilateral lung 
transplantations, except one case (3.6%) in the FEV1 ≥80% 
group and two cases (6.7%) in the FEV1 <80% group. Idiopathic 
pulmonary fibrosis (IPF) was the most common cause of lung 
transplantation in both groups [15 patients (53.6%) in the FEV1 
≥80% group vs. 13 patients (43.3%) in the FEV1 <80% group, 
p=0.550]. The proportions of primary pulmonary diagnoses or 
comorbidities were not statistically different.
Recovery of pulmonary function after transplantation
The postoperative recovery of pulmonary function was assessed 
by PFT. The results are presented in Table 2 and Fig. 2. In pre-
Table 1. Baseline Characteristics of the Recipients
Variables Total (n=58) FEV1≥80% (n=28) FEV1<80% (n=30) p value
Age (yr) 52 (16–69) 55 (16–67) 45 (18–69) 0.004 
≤40 4 (14.3) 10 (33.3)
41–60 19 (67.9) 18 (60.0)
>60 5 (17.9) 2 (6.7)
Gender, male 33 (56.9) 15 (53.6) 18 (60.0) 0.624 
Weight (kg) 56.0 [51.7, 63.5] 58.5 [52.5, 63.3] 54.5 [49.2, 64.0] 0.450 
Height (m) 1.64 [1.60, 1.72] 1.63 [1.59, 1.70] 1.69 [1.60, 1.72] 0.204 
BMI (kg/m2) 20.7 [18.3, 23.3] 22.2 [18.5, 23.6] 20.3 [17.4, 23.3] 0.225 
Smoking* 19 (32.8) 9 (32.1) 10 (33.3) 0.924 
PNI score 46.5 [40.6, 52.0] 44.8 [40.4, 51.8] 47.0 [40.4, 54.1] 0.779 
Transplant type, single 3 (5.2) 1 (3.6) 2 (6.7) 0.598 
Primary diagnosis 0.550 
IPF 28 (48.3) 15 (53.6) 13 (43.3)
CTD related ILD 12 (20.7) 4 (14.3) 8 (26.7)
NSIP 2 (3.4) 2 (7.1) 0 (0.0)
BO after BMT 7 (12.1) 3 (10.7) 4 (13.3)
Bronchiectasis 4 (6.9) 2 (7.1) 2 (6.7)
LAM 3 (5.2) 2 (7.1) 1 (3.3)
Destroyed lung 2 (3.4) 0 (0.0) 2 (6.7)
Comorbidity 0.950 
CTD 12 (20.7) 4 (14.3) 8 (26.7)
Diabetes mellitus 13 (22.4) 10 (35.7) 3 (10.0)
Heart failure 0 (0.0) 0 (0.0) 0 (0.0)
CAOD 5 (8.6) 5 (17.9) 0 (0.0)
Atrial fibrillation 1 (1.7) 0 (0.0) 1 (3.3)
Tuberculosis 11 (19.0) 4 (14.3) 7 (23.3)
NTM 9 (15.5) 5 (17.9) 4 (13.3)
Hematologic malignancy 7 (12.1) 3 (10.7) 4 (13.3)
FEV1, forced expiratory volume in 1 second; BMI, body mass index; PNI, prognostic nutritional index; IQR, interquartile range; IPF, idiopathic pulmonary fibrosis; 
CTD related ILD, connective tissue disease related interstitial lung disease; NSIP, nonspecific interstitial pneumonia; BO, bronchiolitis obliterans; BMT, bone mar-
row transplantation; LAM, lymphangioleiomyomatosis; CTD, connective tissue disease; CAOD, coronary artery occlusive disease; NTM, nontuberculosis myco-
bacterium.
Data are presented as numbers (percentage), median (range), or median [interquartile range].
*≥20 pack year (PYR).
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operative PFTs, the forced vital capacity (FVC) of the FEV1 < 
80% group was lower than that of the FEV1 ≥80% group (45% 
vs. 33%, p=0.019), while FEV1 and forced expiratory flow 25–
75% (FEF 25–75%) were not significantly different before op-
eration between the two groups. After transplantation, PFTs 
were performed at 1, 3, 6, 9, and 12 months after transplanta-
tion. All median values of FVC, FEV1, and FEF 25–75% showed 
better recovery in the FEV1 ≥80% group (FVC: 82% vs. 54%, p< 
0.001; FEV1: 91% vs. 60%, p<0.001; FEF 25–75%: 113% vs. 77%, 
p=0.017).
Perioperative factors associated with lung function 
recovery
Perioperative variables associated with lung function recovery 
are presented in Table 3. Echocardiographic variables and 6- 
minute walk test (6MWT) results were not significantly differ-
ent between the two groups. There was no difference in pre-
operative MV or preoperative ECMO use between the two 
groups. However, the median duration of postoperative MV 
and postoperative ECMO was longer in the FEV1 <80% group 
than in the FEV1 ≥80% group [MV duration; 3 (range, 1–16) vs. 
9 (1–53) days, p=0.017; ECMO duration: 2 (range 1–6) vs. 2 (1–
25) days, p=0.032]. The proportion of tracheostomies was larg-
er in the FEV1 <80% group (17.9% vs. 43.3%, p=0.038). Further-
more, FEV1 <80% group patients were hospitalized for longer 
periods and received longer ICU care than patients in the FEV1 
≥80% group (hospitalization: 30 days vs. 46 days, p=0.003; ICU 
duration: 7 days vs. 13 days, p=0.009). During the postopera-
tive period, four of the FEV1 <80% group patients needed renal 
replacement therapy, while none of the FEV1 ≥80% group re-
quired this therapy [FEV1 ≥80% vs. FEV1 <80%: 0 patients 
(0.0%) vs. 4 patients (13.3%), p=0.047]. At 72 hours after trans-
plantation, compared with the FEV1 ≥80% group, patients 
with FEV1 <80% had more high-grade PGD [FEV1 ≥80% vs. 
FEV1 < 80%: 3 patients (10.7%) vs. 16 patients (53.3%), p=0.001], 
while graft rejection and acute rejection requiring steroid pulse 
treatment within 1 year were not significantly different.
Intraoperative variables are presented in Table 4. The medi-
an time of operation was longer in the FEV1 <80% group than 
in the FEV1 ≥80% group (368 min vs. 415 min, p=0.034), while 
ischemic time, size mismatch, proportion of donor lung wedge 
resection, and re-operation after transplantation were not sig-
nificantly different. There was no difference between the two 
groups in total fluid control, except for the quantity of red blood 
cell transfusion (FEV1 ≥80% vs. FEV1 <80%: 5 packs vs. 7 packs, 
p=0.020).
Characteristics of the donors
Regarding donor variables, there was no significant difference 
between the two groups in regards to age, gender, BMI, smoking 
history, D/R TLC, PaO2/FiO2 ratio, ventilation time, CPR time, 
duration of ICU stay, or chest trauma history. The results are 
shown in Table 5. 
Table 2. Univariate Analysis of Pulmonary Function Tests
Variables
FEV1≥80% (n=28) FEV1<80% (n=30) p value
L, median (IQR) %, median (IQR) L, median (IQR) %, median (IQR) L %
FVC
Before TPL 1.51 (1.18, 1.85) 45 (32, 55) 1.30 (0.84, 1.88) 33 (21, 46) 0.225 0.019
After 1 month of TPL 1.99 (1.73, 2.64) 56 (50, 67) 1.65 (1.36, 2.44) 45 (37, 57) 0.058 0.001
After 3 months of TPL 2.52 (1.95, 2.83) 68 (58, 73) 1.72 (1.48, 2.21) 45 (36, 53) <0.001 <0.001
After 6 months of TPL 2.44 (2.13, 3.20) 74 (62, 83) 2.03 (1.56, 2.70) 55 (41, 64) 0.003 <0.001
After 9 months of TPL 2.85 (2.26, 3.19) 75 (70, 83) 2.07 (1.53, 2.84) 53 (40, 66) 0.002 <0.001
After 1 year of TPL 2.88 (2.40, 3.49) 82 (75, 91) 2.03 (1.64, 3.01) 54 (40, 65) <0.001 <0.001
FEV1
Before TPL 1.06 (0.79, 1.55) 42 (29, 60) 1.13 (0.66, 1.45) 33 (23, 50) 0.715 0.119
After 1 month of TPL 1.82 (1.54, 2.27) 68 (61, 78) 1.60 (1.25, 1.96) 53 (43, 63) 0.072 <0.001
After 3 months of TPL 2.21 (1.83, 2.57) 81 (74, 88) 1.50 (1.34, 1.99) 53 (42, 65) <0.001 <0.001
After 6 months of TPL 2.14 (1.85, 2.67) 86 (75, 92) 1.67 (1.43, 2.18) 62 (48, 67) 0.001 <0.001
After 9 months of TPL 2.31 (2.01, 2.81) 86 (78, 95) 1.64 (1.38, 2.33) 57 (46, 71) 0.001 <0.001
After 1 year of TPL 2.52 (2.02, 2.98) 91 (85, 102) 1.74 (1.36, 2.28) 60 (50, 74) <0.001 <0.001
FEF 25–75%
Before TPL 1.82 (0.51, 3.11) 61 (16, 105) 2.00 (0.92, 3.28) 62 (28, 94) 0.638 0.987
After 1 month of TPL 3.36 (1.67, 4.23) 115 (83, 139) 2.67 (1.85, 3.39) 77 (58, 102) 0.218 0.006
After 3 months of TPL 3.58 (2.87, 4.58) 129 (97, 167) 2.75 (1.85, 3.58) 86 (60, 102) <0.001 <0.001
After 6 months of TPL 3.22 (2.43, 4.17) 117 (85, 146) 2.35 (1.93, 3.33) 71 (64, 104) 0.065 0.004
After 9 months of TPL 2.99 (2.42, 3.84) 103 (81, 121) 2.50 (1.60, 3.91) 72 (54, 121) 0.338 0.058
After 1 year of TPL 3.15 (2.29, 4.23) 113 (77, 132) 2.69 (1.61, 3.71) 77 (54, 117) 0.122 0.017 
TPL, transplantation; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF 25–75%, forced expiratory flow 25–75%; IQR, interquartile range.
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Multivariate analysis of the variables
Multivariate analysis revealed that younger recipients [odds ra-
tio (OR), 0.92; 95% confidential interval (CI), 0.87–0.98; p=0.010], 
longer duration of MV use after surgery (OR, 1.14; 95% CI, 
1.03–1.26; p=0.015), and high-grade PGD (OR, 8.08; 95% CI, 
1.67–39.18; p=0.009) were independent risk factors associated 
with a lack of full recovery of lung function at 1 year after lung 
transplantation (Table 6).
DISCUSSION
Lung transplants are increasing worldwide. According to the 
ISHLT registry, a total of 60107 lung transplants had been per-
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formed by June 2016, although with a median survival of 6.0 
years. While the median survival of lung transplant patients im-
proves slightly (up to 8.1 years) in those surviving more than one 
year after surgery, it remains lower than the survival rate of other 
solid organ transplants.2 Therefore, most previous studies have 
involved finding survival-related risk factors to improve the over-
all survival of lung transplant recipients.4-9 Meanwhile, a com-
parative study of the recovery of pulmonary function in surviv-
ing patients has not been a research priory. While there are some 
patients whose lung function recovers well, there are some who 
fail to fully recover lung function. The purpose of this study was 
to investigate factors affecting pulmonary function recovery in 
patients surviving at least 1 year after lung transplantation.
In our study, younger recipients, a longer duration of MV use 
after surgery, and high-grade PGD were independent risk fac-
tors associated with a lack of full recovery of lung function at 1 
Table 3. Univariate Analysis of Perioperative Variables
Variables
FEV1≥80% 
(n=28)
FEV1<80% 
(n=30)
p 
value
MV apply before TPL 5 (17.9) 8 (26.7) 0.425 
ECMO apply before TPL 2 (7.1) 7 (23.3) 0.092 
MV duration after TPL (day) 3 (1–16) 9 (1–53) 0.017 
ECMO duration after TPL (day) 2 (1–6) 2 (1–25) 0.032 
ECMO weaning within 24 hours 6 (21.4) 11 (36.7) 0.207 
Tracheostomy 5 (17.9) 13 (43.3) 0.038 
Intensive care unit stay (day) 7 (3–37) 13 (3–54) 0.009 
Hospitalization days 30 (15–78) 46 (18–198) 0.003 
HD usage after TPL 0 4 (13.3) 0.047 
PaO2/FiO2 ratio after 48 hours 386 [313, 433] 333 [238, 404] 0.032 
PaO2/FiO2 ratio after 72 hours 383 [319, 484] 294 [231, 422] 0.009 
Primary graft dysfunction
Grade 0–1 25 (89.3) 14 (46.7)
Grade 2–3 3 (10.7) 16 (53.3) 0.001 
Steroid pulse treatment 1 (3.6) 4 (13.3) 0.189
Echocardiography, before TPL
EF (%) 62 [59, 71] 65 [61, 68] 0.681 
E/E' 8 [7, 10] 9 [7, 11] 0.678 
TAPSE (cm) 1.48 [1.16, 1.60] 1.50 [1.40, 1.85] 0.615 
RVSP (mm Hg) 51 [40, 70] 45 [30, 67] 0.459 
RWMA 8 (28.6) 3 (10.0) 0.074 
Echocardiography, after TPL
EF after TPL (%) 64 [59, 68] 65 [58, 75] 0.445 
E/E' 9 [6, 10] 10 [8, 11] 0.438 
RVSP (mm Hg) 31 [24, 36] 26 [22, 33] 0.229 
RWMA 3 (10.7) 0 (0.0) 0.068 
6 minute walk test (m)
Before TPL 160 [105, 327] 295 [150, 375] 0.281 
After 1 month of TPL 337 [284, 415] 343 [200, 460] 0.789 
After 3 months of TPL 390 [360, 510] 400 [250, 480] 0.291 
After 6 months of TPL 445 [400, 497] 445 [400, 490] 0.638 
After 1 year of TPL 500 [432, 552] 460 [335, 542] 0.096 
FEV1, forced expiratory volume in 1 second; MV, mechanical ventilation; TPL, 
transplantation; ECMO, extracorporeal membrane oxygenation; HD, hemodi-
alysis; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxy-
gen; EF, ejection fraction; E/E', the ratio of mitral peak velocity of early filling 
(E) to early diastolic mitral annular velocity (E'); TAPSE, tricuspid annular 
plane systolic excursion; RVSP, right ventricular systolic pressure; RWMA, 
regional wall motion abnormalities.
Data are presented as numbers (percentage), median (range), or median [inter-
quartile range].
Table 4. Univariate Analysis of Variables Related with Transplantation 
Surgery
Variables
FEV1≥80% 
(n=28)
FEV1<80% 
(n=30)
p 
value
Ischemic time (min) 229 [183, 292] 237 [189, 318] 0.720 
Operation time (min) 368 [352, 439] 415 [374, 481] 0.034 
Size mismatch 4 (14.3) 2 (6.7) 0.620 
Donor lung wedge resection 6 (21.4) 11 (36.7) 0.207 
Re-operation after TPL 5 (17.9) 9 (30.0) 0.284 
Input fluid (mL) 6950 [5385, 8625] 7425 [6485, 9675] 0.246 
Input blood (mL) 2190 [1491, 2812] 2762 [1250, 3904] 0.392 
Output urine (mL) 1485 [815, 1997] 1105 [792, 1955] 0.423 
Output blood (mL) 1510 [912, 2875] 2000 [1475, 3300] 0.105 
Total input/output (mL) 5771 [3537, 7563] 7290 [4582, 8231] 0.222 
Transfusion (packs)
Red blood cell 5 [3, 7] 7 [4, 12] 0.020 
Fresh frozen plasma 3 [2, 4] 1 [0, 5] 0.109 
Platelet 6 [0, 11] 4 [0, 12] 0.921 
TPL, transplantation; FEV1, forced expiratory volume in 1 second; IQR, inter-
quartile range.
Data are presented as numbers (percentage) or median [interquartile range].
Table 5. Univariate Analysis of Variables Related with Donors
Variables
FEV1≥80% 
(n=28)
FEV1<80% 
(n=30)
p 
value
Age (yr) 46 (16–59) 42 (12–59) 0.293 
Gender, male 15 (53.6) 21 (70.0) 0.201 
Weight (kg) 63.8 [58.2, 76.0] 60.0 [53.1, 69.0] 0.188 
Height (m) 1.68 [1.60, 1.73] 1.67 [1.62, 1.72] 0.919 
BMI (kg/m2) 23.0 [20.9, 25.1] 22.1 [20.5, 24.4] 0.208 
Smoking 6 (21.4) 5 (16.7) 0.647 
R-TLC 5.391 [4.712, 5.930] 5.845 [4.938, 6.214] 0.090 
D-TLC 5.834 [4.732, 6.380] 5.823 [5.001, 6.363] 0.560 
D/R TLC 108.9 [99.5, 119.1] 101.5 [92.5, 116.1] 0.161 
PaO2 (mm Hg) 465.4 [391.0, 501.8] 442.4 [382.0, 518.0] 0.697 
FiO2 (%) 100 [100, 100] 100 [100, 100] 1.000 
PaO2/FiO2 ratio 465 [391, 501] 442 [382, 518] 0.697 
Ventilation time (hr) 136 [29–808] 137 [37–506] 0.624 
CPR time (min) 0 (0–60) 1 (0–60) 0.873 
Intensive care unit stay (day) 6 (2–34) 6 (2–21) 0.876 
Chest trauma 1 (3.6) 5 (16.7) 0.105 
FEV1, forced expiratory volume in 1 second; BMI, body mass Index; TLC, total 
lung capacity; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired 
oxygen.
Data are presented as numbers (percentage), median (range), or median [inter-
quartile range].
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year after lung transplantation. According to the 2017 ISHLT 
registry report, an older recipient age is associated with a high-
er rate of mortality in the first year.2 The current study applied 
an analysis of only surviving patients; we excluded those who 
expired within the first year of transplantation. Comparing the 
baseline characteristics of the patients excluded from and in-
cluded within the study, we noted that the median age of the 
excluded patients was significantly higher (included patients 
vs. excluded patients: 52 years, range 16–69 years vs. 61 years, 
range 16–75 years; p<0.001). Therefore, it is difficult to inter-
pret age as a significant risk factor for the lack of full recovery 
of lung function among survivors.
Comparing reasons for lung transplantation according to age, 
we found that IPF was the most common cause in patients over 
40 years of age [age ≤40 vs. age >40: 3 patients (21.4%) vs. 25 
patients (56.8%), p=0.022]. However, in individuals under 40 
years of age, transplantation was most frequently performed 
because of bronchiolitis obliterans after bone marrow trans-
plantation [age ≤40 vs. age >40: 5 patients (35.7%) vs. 2 patients 
(4.5%), p=0.002]. According to the ISHLT registry, infection is 
the most common cause of death within 1 year after lung trans-
plantation.2 In patients with Graft-Versus-Host disease, mucosal 
barriers are also affected, and susceptibility to infections is in-
creased, affecting lung function recovery.17
One study has described a relationship between PGD at 72 
hours after transplantation and 6MWT performance.18 In our 
study, high-grade PGD was more common in the FEV1 <80% 
group. Although there was no significant difference in 6MWT 
after 1, 3, 6, and 12 months of transplantation in our study, we 
did exclude patients who did not undergo PFT, which may ac-
count for the discrepancy between the results of this and the 
aforementioned study. We suspect that PGD may have a neg-
ative effect on functional status after lung transplantation.
Interestingly, we noted no relationship between MV or ECMO 
application before transplantation and recovery of pulmonary 
function after transplantation. However, there was a signifi-
cant difference therein during the postoperative period. In the 
FEV1 <80% group, the duration of MV or ECMO usage was lon-
ger and tracheostomies were performed more frequently dur-
ing the postoperative period. Additionally, univariate analysis 
revealed significant differences in the use of renal replacement 
therapy, ICU stay, and total hospitalization days. These find-
ings suggested that immediate postoperative graft function re-
covery is an important factor for prognosis. In multivariate pre-
dictive models of overall mortality recorded in the 2017 ISHLT 
registry, only allograft ischemic time was identified as an oper-
ative variable for prediction models. Although we did not ana-
lyze mortality, our results indicate that the degree of lung func-
tion recovery can influence overall survival, consistent with 
previous studies.2,9
This study has limitations in that it was performed on a small 
number of subjects from a single institution. Age can be con-
sidered an important factor; however, older adult patients were 
generally excluded from this study. Thus, we could not clarify 
the correlation between age and pulmonary function recovery. 
Among the components that were used to grade the degree of 
PGD, chest radiographs were difficult to interpret because they 
included mixed infiltration by pulmonary edema, infection, and 
changes due to vascular complications or postoperative chang-
es. Further research including additional patients from multiple 
centers, as well as more clarified clinical factors, is needed. Nev-
ertheless, our study has strengths. To date, many studies have 
been conducted to investigate mortality after transplantation. 
However, depending on lung function recovery, survivors may 
have a very different quality of life. Thus, in this study, we evalu-
ated factors affecting pulmonary function recovery in patients 
who survived more than one year. This study lays the ground-
work for further study.
In conclusion, postoperative MV duration and graft dysfunc-
tion at 72 hours were identified as important factors affecting 
lung function recovery after the first year of lung transplantation. 
Therefore, immediate postoperative status may be associated 
with recovery of lung function after lung transplantation. Clini-
cians should carefully follow the degree of PFT in lung trans-
plant patients who experience postoperative complications. 
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